TZ9
TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and apoptosis, and inhibits the proliferation and migration of metastatic human breast cancer cells[1].
Product Specifications
CAS Number
[1002789-86-7]
UNSPSC
12352005
Target
Apoptosis; E1/E2/E3 Enzyme
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/TZ9.html
Concentration
10mM
Purity
99.45
Solubility
DMSO : ≥ 40 mg/mL
Smiles
O=C(OCC1=NC(N)=NC(NC2=CC=CC=C2)=N1)C3=CC=C([N+]([O-])=O)C=C3
Molecular Formula
C17H14N6O4
Molecular Weight
366.33
References & Citations
[1]Sanders MA, et al. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization. Mol Cancer Ther. 2013 Apr;12 (4) :373-83.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
EKN48846 96 Tests
Rabbit Tissue Inhibitors Of Metalloproteinase 4 (TIMP4) ELISA Kit
Ask
View Details MBS6499482-01 0.2 mL
Siglec 11, CT (Sialic Acid-binding Ig-like Lectin 11, Sialic Acid-binding Lectin 11, Siglec 11, UNQ9222/PRO28718) (FITC)
Ask
View Details MBS6499482-02 5x 0.2 mL
Siglec 11, CT (Sialic Acid-binding Ig-like Lectin 11, Sialic Acid-binding Lectin 11, Siglec 11, UNQ9222/PRO28718) (FITC)
Ask
View Details